Heparin-induced thrombocytopenia: a review of current pharmacologic treatment.
Talati
Ripple
R
Cardiovascular Pharmacology, Hartford Hospital, Hartford, USA.
Colemen
Craig I
CI
White
C Michael
CM
D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use*; D000990:Antithrombin III / Q000627:therapeutic use; D001120:Arginine / Q000031:analogs & derivatives; D000077425:Fondaparinux; D006493:Heparin / Q000009:adverse effects*; D006629:Hirudins; D006801:Humans; D010875:Pipecolic Acids / Q000627:therapeutic use*; D011134:Polysaccharides / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*
D000925:Anticoagulants; D006629:Hirudins; D010875:Pipecolic Acids; D011134:Polysaccharides; D011994:Recombinant Proteins; D013449:Sulfonamides; D000990:Antithrombin III; D006493:Heparin; D001120:Arginine; D013917:Thrombin; C031942:argatroban; D000077425:Fondaparinux; C083544:lepirudin